Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Collegium Pharmaceutical (COLL) Debt to Equity (2016 - 2025)

Historic Debt to Equity for Collegium Pharmaceutical (COLL) over the last 10 years, with Q3 2025 value amounting to $2.07.

  • Collegium Pharmaceutical's Debt to Equity fell 2288.15% to $2.07 in Q3 2025 from the same period last year, while for Sep 2025 it was $2.07, marking a year-over-year decrease of 2288.15%. This contributed to the annual value of $2.69 for FY2024, which is 2973.33% up from last year.
  • Per Collegium Pharmaceutical's latest filing, its Debt to Equity stood at $2.07 for Q3 2025, which was down 2288.15% from $2.52 recorded in Q2 2025.
  • Over the past 5 years, Collegium Pharmaceutical's Debt to Equity peaked at $3.2 during Q1 2022, and registered a low of $0.49 during Q3 2021.
  • Its 5-year average for Debt to Equity is $2.11, with a median of $2.51 in 2023.
  • As far as peak fluctuations go, Collegium Pharmaceutical's Debt to Equity tumbled by 5446.04% in 2021, and later soared by 50857.34% in 2022.
  • Quarter analysis of 5 years shows Collegium Pharmaceutical's Debt to Equity stood at $0.54 in 2021, then skyrocketed by 430.2% to $2.87 in 2022, then decreased by 27.9% to $2.07 in 2023, then rose by 29.73% to $2.69 in 2024, then fell by 22.84% to $2.07 in 2025.
  • Its last three reported values are $2.07 in Q3 2025, $2.52 for Q2 2025, and $2.56 during Q1 2025.